AMENDMENTS TO THE CLAIMS

1. (previously presented) A crystal of ACE protein.

2. (previously presented) A crystal according to claim 1 wherein the ACE protein is underglycosylated.

3. (previously presented) A crystal according to claim 2 wherein the ACE protein is underglycosylated by removing one or more glycosylation sites and/or one or more partially glycosylated sites.

4. (currently amended) A crystal according to claim 3 wherein the underglycosylated ACE protein comprises a mutation at amino acid 337 or amino acid ~~90,109, 155,337 and 586 ofSEQ ID No 2~~90, 109, 155, 337 and 586 of SEQ ID No 2.

5. (previously presented) A crystal according to claim 1 comprising atoms arranged in a spatial relationship represented by at least a portion of the structure co-ordinates of Table A or Table B.

6. (currently amended) A crystal according to claim 1 wherein the crystal belongs to the space group $P2_12_12_1$ or wherein the crystal has the unit cell dimensions: a=56.47 Å, b=84.90 Å and c=133.99 Å.

7. (canceled)

8. (previously presented) A crystal according to claim 1 wherein the crystal is a crystal of human ACE protein.

9. (previously presented) A crystal according to claim 1 wherein the crystal further comprises an entity bound to the ACE protein or a portion thereof.

10. (currently amended) A crystal according to claim 9 wherein the entity is bound to the ACE protein or a portion thereof by contacting one or more residues of the ACE protein selected from : ~~His384,Ala385, Lys542, Tyr551, Tyr554,Glu415~~His384, Ala385, Lys542, Tyr551, Tyr554, Glu415 and His544.

11. (previously presented) A crystal according to claim 9 wherein the entity modulates the activity of ACE.

12. (previously presented) A crystal according to claim 11 wherein the entity is an inhibitor of ACE.

13. (previously presented) A crystal according to claim 12 wherein the inhibitor of ACE is lisinopril or a derivative thereof.

14. (previously presented) A crystal according to claim 13 comprising atoms arranged in a spatial relationship represented by at least a portion of the structure co-ordinates of Table B.

15. (previously presented) A method of preparing a crystal of ACE protein comprising the steps of :

(a) culturing host cells comprising an underglycosylated ACE protein;

(b) purifying the underglycosylated ACE protein; and

(c) crystallising the underglycosylated ACE protein.

16. (previously presented) A method according to claim 15 wherein the ACE protein is underglycosylated by removing one or more glycosylation sitesand/or one or more partially glycosylated sites.

17. (currently amended) A method according to claim 15 wherein the underglycosylated ACE protein comprises a mutation at amino acid 337 of SEQ ID No 2 or amino acids ~~90,109, 155,337~~90, 109, 155, 337 and 586 of SEQ ID No 2.

18. (previously presented) A method according claim 15 wherein the ACE protein is crystallised using about 10 mM HEPES and about 0. 1% PMSF with an equal volume of a reservoir solution containing about 15 % PEG 4000, about 50 mM $CH_3COONa.3H_20$ pH 4.7 and about 10 μM $ZnS0_4.7H_20$.

19. (previously presented) A method according claim 15 wherein the crystal that is prepared has a structure defined by at least a portion of the structure co-ordinates of Table A.

20. (currently amended) A method according claim 15 wherein the crystal belongs to the space group $P2_12_12_1$ or wherein the crystal has the unit cell dimensions: a=56.47 Å, b=84.90 Å and c=133.99 Å.

21. (canceled)

22. (previously presented) A method according to claim 15 wherein the ACE protein is human ACE protein.

23. (previously presented) A method according to claim 15 wherein the ACE protein is crystallised in the presence of an entity.

24. (previously presented) A method according to claim 23 wherein the entity is a modulator of ACE.

25. (previously presented) A method according to claim 24 wherein the entity is an inhibitor of ACE.

26. (previously presented) A method according to claim 25 wherein the inhibitor of ACE is lisinopril or a derivative thereof.

27. (previously presented) A method according to claim 26 wherein the crystal that is prepared has a structure defined by at least a portion of the structure co-ordinates of Table B.

28-35. (canceled)

36. (withdrawn-currently amended) A method of screening for a modulator of ACE wherein the method comprises the use of a crystal according to claim 1 and~~according to claim 28~~ wherein the ACE modulator is useful in the prevention and/or treatment of an ACE related disorder.

37. (withdrawn-previously presented) A method according to claim 36 wherein the ACE related disorder is hypertension.

38-44. (canceled)

45. (withdrawn-currently amended) A method of preventing and/or treating an ACE related disorder comprising administering a modulator of ACE ~~according to claim 42~~ wherein said modulator of ACE is capable of causing a beneficial preventative and/or therapeutic effect and wherein said modulator is identified by a screening method that comprises the use of a crystal according to claim 1.

46-60. (canceled)